Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Individual- and Ad-Level Predictors of Perceptions of Serious and Actionable Risks in Direct-to-Consumer Prescription Drug TV Advertising.

Aikin KJ, Boudewyns V, Betts KR, Southwell BG, Williams P.

J Health Commun. 2019;24(5):536-546. doi: 10.1080/10810730.2019.1632396. Epub 2019 Jun 28.

PMID:
31253071
2.

Taking Repeated Exposure into Account: An Experimental Study of Direct-To-Consumer Prescription Drug Television Ad Effects.

Betts KR, Aikin KJ, Kelly BJ, Johnson M, Parvanta S, Southwell BG, Mack N, Tzeng J, Cameron L.

J Health Commun. 2019;24(5):503-511. doi: 10.1080/10810730.2019.1609139. Epub 2019 Apr 29.

PMID:
31033396
3.

Direct-to-Consumer Advertising of Prescription Drugs and the Patient-Prescriber Encounter: A Systematic Review.

DeFrank JT, Berkman ND, Kahwati L, Cullen K, Aikin KJ, Sullivan HW.

Health Commun. 2019 Apr 11:1-8. doi: 10.1080/10410236.2019.1584781. [Epub ahead of print]

PMID:
30973021
4.

Actors in whitespace: Communicating risk information on pharmaceutical websites.

O'Donoghue AC, Sullivan HW, Rupert DJ, Fitts Willoughby J, Aikin KJ.

Health Mark Q. 2019 Apr-Jun;36(2):152-167. doi: 10.1080/07359683.2019.1575063. Epub 2019 Mar 23.

PMID:
30907290
5.

Consumer tradeoff of advertising claim versus efficacy information in direct-to-consumer prescription drug ads.

Aikin KJ, Betts KR, Ziemer KS, Keisler A.

Res Social Adm Pharm. 2019 Feb 4. pii: S1551-7411(19)30026-9. doi: 10.1016/j.sapharm.2019.01.012. [Epub ahead of print]

PMID:
30846370
6.

Testimonials and Informational Videos on Branded Prescription Drug Websites: Experimental Study to Assess Influence on Consumer Knowledge and Perceptions.

Sullivan HW, O'Donoghue AC, Gard Read J, Amoozegar JB, Aikin KJ, Rupert DJ.

J Med Internet Res. 2018 Jan 23;20(1):e13. doi: 10.2196/jmir.7959.

7.

Communicating Risk Information in Direct-to-Consumer Prescription Drug Television Ads: A Content Analysis.

Sullivan HW, Aikin KJ, Poehlman J.

Health Commun. 2019 Feb;34(2):212-219. doi: 10.1080/10410236.2017.1399509. Epub 2017 Nov 10.

PMID:
29125325
8.

Serious and actionable risks, plus disclosure: Investigating an alternative approach for presenting risk information in prescription drug television advertisements.

Betts KR, Boudewyns V, Aikin KJ, Squire C, Dolina S, Hayes JJ, Southwell BG.

Res Social Adm Pharm. 2018 Oct;14(10):951-963. doi: 10.1016/j.sapharm.2017.07.015. Epub 2017 Aug 2.

PMID:
28844621
9.

Direct-to-Consumer Promotion of Prescription Drugs on Mobile Devices: Content Analysis.

Aikin KJ, Sullivan HW, Dolina S, Lynch M, Squiers LB.

J Med Internet Res. 2017 Jul 4;19(7):e225. doi: 10.2196/jmir.7306.

10.

Prescribers' Knowledge and Skills for Interpreting Research Results: A Systematic Review.

Kahwati L, Carmody D, Berkman N, Sullivan HW, Aikin KJ, DeFrank J.

J Contin Educ Health Prof. 2017 Spring;37(2):129-136. doi: 10.1097/CEH.0000000000000150. Review.

PMID:
28562502
11.

Placement and Format of Risk Information on Direct-to-Consumer Prescription Drug Websites.

Sullivan HW, O'Donoghue AC, Rupert DJ, Willoughby JF, Aikin KJ.

J Health Commun. 2017 Feb;22(2):171-181. doi: 10.1080/10810730.2016.1258745. Epub 2017 Jan 27.

PMID:
28129069
12.

Consumer perceptions of prescription and over-the-counter drug advertisements with promotional offers.

Aikin KJ, Sullivan HW, O'Donoghue AC, Betts KR.

Health Mark Q. 2016 Oct-Dec;33(4):291-306. Epub 2016 Oct 19.

PMID:
27841741
13.

Are Disease Awareness Links on Prescription Drug Websites Misleading? A Randomized Study.

Sullivan HW, O'Donoghue AC, Rupert DJ, Willoughby JF, Amoozegar JB, Aikin KJ.

J Health Commun. 2016 Nov;21(11):1198-1207. Epub 2016 Nov 2.

PMID:
27805473
14.

Quantitative Information on Oncology Prescription Drug Websites.

Sullivan HW, Aikin KJ, Squiers LB.

J Cancer Educ. 2018 Apr;33(2):371-374. doi: 10.1007/s13187-016-1107-1.

15.

Professional online community membership and participation among healthcare providers: An extension to nurse practitioners and physician assistants.

Betts KR, O'Donoghue AC, Aikin KJ, Kelly BJ, Boudewyns V.

J Am Assoc Nurse Pract. 2016 Dec;28(12):639-645. doi: 10.1002/2327-6924.12383. Epub 2016 May 23.

PMID:
27214569
16.

Correction of misleading information in prescription drug television advertising: The roles of advertisement similarity and time delay.

Aikin KJ, Southwell BG, Paquin RS, Rupert DJ, O'Donoghue AC, Betts KR, Lee PK.

Res Social Adm Pharm. 2017 Mar - Apr;13(2):378-388. doi: 10.1016/j.sapharm.2016.04.004. Epub 2016 Apr 22.

PMID:
27178746
17.

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration.

Sullivan HW, Aikin KJ, Chung-Davies E, Wade M.

PLoS One. 2016 May 5;11(5):e0155035. doi: 10.1371/journal.pone.0155035. eCollection 2016.

18.

Who Said It Better? A Test of Wording Differences in the MedWatch "Toll-Free Statement" for Consumer Reporting of Side Effects in Direct-to-Consumer Television Advertisements.

Aikin KJ, O'Donoghue AC, Sullivan HW, Betts KR, Squire C.

Ther Innov Regul Sci. 2016 Mar;50(2):169-173. doi: 10.1177/2168479015596023.

PMID:
30227007
19.

Visual presentations of efficacy data in direct-to-consumer prescription drug print and television advertisements: A randomized study.

Sullivan HW, O'Donoghue AC, Aikin KJ, Chowdhury D, Moultrie RR, Rupert DJ.

Patient Educ Couns. 2016 May;99(5):790-9. doi: 10.1016/j.pec.2015.12.015. Epub 2015 Dec 22.

PMID:
26749356
20.

Disease Information in Direct-to-Consumer Prescription Drug Print Ads.

Aikin KJ, Sullivan HW, Betts KR.

J Health Commun. 2016;21(2):228-39. doi: 10.1080/10810730.2015.1058440. Epub 2015 Dec 30.

PMID:
26717304
21.

Awareness of the Food and Drug Administration's Bad Ad Program and Education Regarding Pharmaceutical Advertising: A National Survey of Prescribers in Ambulatory Care Settings.

O'Donoghue AC, Boudewyns V, Aikin KJ, Geisen E, Betts KR, Southwell BG.

J Health Commun. 2015;20(11):1330-6. doi: 10.1080/10810730.2015.1018649. Epub 2015 Jul 15.

PMID:
26176326
22.

Communicating Benefit and Risk Information in Direct-to-Consumer Print Advertisements: A Randomized Study.

Sullivan HW, O'Donoghue AC, Aikin KJ.

Ther Innov Regul Sci. 2015 Jul;49(4):493-502. doi: 10.1177/2168479015572370.

PMID:
30222437
23.

Primary care physicians' use of FDA-approved prescription drug labels.

Sullivan HW, O'Donoghue AC, Aikin KJ.

J Am Board Fam Med. 2014 Sep-Oct;27(5):694-8. doi: 10.3122/jabfm.2014.05.140039.

24.

Important Safety Information or Important Risk Information? A Question of Framing in Prescription Drug Advertisements.

O'Donoghue AC, Sullivan HW, Aikin KJ, Betts KR.

Ther Innov Regul Sci. 2014 May;48(3):305-307. doi: 10.1177/2168479013510306.

PMID:
30235532
25.

Randomized study of placebo and framing information in direct-to-consumer print advertisements for prescription drugs.

O'Donoghue AC, Sullivan HW, Aikin KJ.

Ann Behav Med. 2014 Dec;48(3):311-22. doi: 10.1007/s12160-014-9603-1.

PMID:
24682975
26.

Presenting efficacy information in direct-to-consumer prescription drug advertisements.

O'Donoghue AC, Sullivan HW, Aikin KJ, Chowdhury D, Moultrie RR, Rupert DJ.

Patient Educ Couns. 2014 May;95(2):271-80. doi: 10.1016/j.pec.2013.12.010. Epub 2013 Dec 25.

PMID:
24581929
27.

Presenting quantitative information about placebo rates to patients.

Sullivan HW, O'Donoghue AC, Aikin KJ.

JAMA Intern Med. 2013 Nov 25;173(21):2006-7. doi: 10.1001/jamainternmed.2013.10399. No abstract available.

PMID:
24126622
28.

Despite 2007 law requiring FDA hotline to be included in print drug ads, reporting of adverse events by consumers still low.

Du D, Goldsmith J, Aikin KJ, Encinosa WE, Nardinelli C.

Health Aff (Millwood). 2012 May;31(5):1022-9. doi: 10.1377/hlthaff.2010.1004.

PMID:
22566442
29.

Randomized trial of risk information formats in direct-to-consumer prescription drug advertisements.

Aikin KJ, O'Donoghue AC, Swasy JL, Sullivan HW.

Med Decis Making. 2011 Nov-Dec;31(6):E23-33. doi: 10.1177/0272989X11413289. Epub 2011 Jun 20.

PMID:
21690303
30.

Supplemental Content

Loading ...
Support Center